Vitenskapelig artikkel

• Sorbye, Halfdan; Hjortland, Geir Olav; Vestermark, Lene Weber et al. (2025). Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study: Clinical Studies. (ekstern lenke)
• Ree, Anne Hansen; Saltyte Benth, Jurate; Hamre, Hanne Mari et al. (2024). First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial. (ekstern lenke)
• Hamfjord, Julian; Guren, Tormod Kyrre; Glimerius, Bengt et al. (2024). Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer. (ekstern lenke)
• Ree, Anne Hansen; Høye, Eirik; Esbensen, Qin Ying et al. (2024). Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. (ekstern lenke)
• Kinos, Sampsa; Hagman, Helga; Halonen, Päivi et al. (2024). Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study). (ekstern lenke)
• Sorbye, Halfdan; Hjortland, Geir Olav; Vestermark, L.W. et al. (2024). NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Elvebakken, Hege; Venizelos, Andreas; Perren, Aurel et al. (2024). Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms. (ekstern lenke)
• Liposits, Gabor; Winther, Stine B.; Ryg, Jesper et al. (2023). The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study. (ekstern lenke)
• Steen, Synne Wollen; Sorbye, Halfdan; Jazbani, Mehran et al. (2023). Takotsubosyndrom under behandling med fluorouracil. (ekstern lenke)
• Sorbye, Halfdan; Grande, Enrique; Pavel, Marianne et al. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. (ekstern lenke)
• Osterlund, Emerik; Ristimäki, Ari; Mäkinen, Markus J. et al. (2023). Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. (ekstern lenke)
• Papantoniou, Dimitrios; Grönberg, Malin; Thiis-Evensen, Espen et al. (2023). Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. (ekstern lenke)
• Elvebakken, Hege; Hjortland, Geir Olav; Garresori, Herish et al. (2023). Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Morken, Siren; Langer, Seppo W.; Sundlöv, Anna et al. (2023). Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Venizelos, Andreas; Sorbye, Halfdan; Elvebakken, Hege et al. (2023). Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Knappskog, Stian; Grob, Tobias; Venizelos, Andreas et al. (2023). Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma. (ekstern lenke)
• Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein et al. (2022). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. (ekstern lenke)
• Osterlund, P.; Kinos, S.; Pfeiffer, P. et al. (2022). Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. (ekstern lenke)
• Dasari, Arvind; Shen, Chan; Devabhaktuni, Anjali et al. (2022). Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. (ekstern lenke)
• Osterlund, Emerik; Ristimäki, Ari; Kytölä, Soili et al. (2022). KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer. (ekstern lenke)
• Thiis-Evensen, Espen; Kjellman, Magnus; Knigge, Ulrich et al. (2022). Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. (ekstern lenke)
• Meltzer, Sebastian; Negård, Anne; Bakke, Kine Mari et al. (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. (ekstern lenke)
• Liposits, Gabor; Skuladottir, Halla; Ryg, Jesper et al. (2022). The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—The Randomized NORDIC9-Study. (ekstern lenke)
• Liposits, Gabor Isivan; Ryg, Jesper; Skuladottir, Halla et al. (2022). Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study. (ekstern lenke)
• Langen Stokmo, Henning; Aly, Mahmoud; Lothe, Inger Marie Bowitz et al. (2022). Volumetric parameters from [18F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Aasebø, Kristine Øverås; Bruun, Jarle; Bergsland, Christian Holst et al. (2022). Prognostic role of tumour infiltrating lymphocytes and macrophages in relation to tumour MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. (ekstern lenke)
• Falk, Philip; Severin, Mira; Berglund, Åke et al. (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. (ekstern lenke)
• Liposits, Gabor; Eshoj, Henrik; Möller, Sören et al. (2021). Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—the randomized NORDIC9-study. (ekstern lenke)
• Pommergaard, Hans-Christian; Nielsen, Kirstine; Sorbye, Halfdan et al. (2021). Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. (ekstern lenke)
• Vogt, Elinor Margrethe Chelsom; Hammerling, Katrin; Sorbye, Halfdan et al. (2021). Feminizing adrenal tumor identified by plasma steroid profiling. (ekstern lenke)
• Venizelos, Andreas; Elvebakken, Hege; Perren, Aurel et al. (2021). The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Hicks, Rodney J.; Dromain, Clarisse; De Herder, Wouter et al. (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. (ekstern lenke)
• Rinke, Anja; Auernhammer, Christoph J.; Bodei, Lisa et al. (2021). Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. (ekstern lenke)
• Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein et al. (2021). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. (ekstern lenke)
• Hamfjord, Julian; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2021). Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. (ekstern lenke)
• Janson, Eva Tiensuu; Knigge, Ulrich; Dam, Gitte et al. (2021). Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Nunes, Luís; Aasebø, Kristine; Mathot, Lucy et al. (2020). Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. (ekstern lenke)
• Sorbye, Halfdan; Meyer, Liv Sylvi; Mordal, Kjerstin Elisabeth Skrede et al. (2020). Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. (ekstern lenke)
• Elvebakken, Hege; Perren, Aurel; Scoazec, Jean-Yves et al. (2020). A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. (ekstern lenke)
• Kjellman, Magnus; Knigge, Ulrich; Welin, Staffan et al. (2020). A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors. (ekstern lenke)
• Dam, Gitte; Grønbæk, Henning; Sorbye, Halfdan et al. (2020). Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. (ekstern lenke)
• Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus et al. (2020). CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup . (ekstern lenke)
• Ali, Abir Salwa; Perren, Aurel; Lindskog, Cecilia et al. (2020). Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. (ekstern lenke)
• Ali, Abir Salwa; Langer, Seppo W.; Federspiel, Birgitte et al. (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. (ekstern lenke)
• Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan et al. (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. (ekstern lenke)
• Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan et al. (2019). Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. (ekstern lenke)
• Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav et al. (2019). Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. (ekstern lenke)
• Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus et al. (2019). Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. (ekstern lenke)
• Winther, Stine Brændegaard; Liposits, Gabor Isivan; Skuladottir, Halla et al. (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. (ekstern lenke)
• Mezheyeuski, Artur; Pontén, Fredrik; Edqvist, Per-Henrik et al. (2019). Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. (ekstern lenke)
• Sorbye, Halfdan; Baudin, Eric; Borbath, Ivan et al. (2019). Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (ekstern lenke)
• Goey, Kaitlyn K.H.; Sorbye, Halfdan; Glimelius, Bengt et al. (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (ekstern lenke)
• Bjørnelv, Gudrun Maria Waaler; Dueland, Svein; Line, Pål Dag et al. (2018). Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.. (ekstern lenke)
• Sorbye, Halfdan; Baudin, Eric; Perren, Aurel (2018). The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. (ekstern lenke)
• Thomsen, Maria; Skovlund, Eva; Sorbye, Halfdan et al. (2018). Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. (ekstern lenke)
• Ali, Abir Salwa; Grönberg, Malin; Langer, Seppo Wang et al. (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (ekstern lenke)
• Dasari, Arvind; Mehta, Kathan; Byers, Lauren Averett et al. (2018). Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. (ekstern lenke)
• Galleberg, Renate Berget; Knigge, Ulrich Peter; Tiensuu Janson, Eva M. et al. (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. (ekstern lenke)
• Guren, Tormod Kyrre; Thomsen, Maria; Kure, Elin H. et al. (2017). Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. (ekstern lenke)
• Siesing, Christina; Sorbye, Halfdan; Dragomir, Anca et al. (2017). High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. (ekstern lenke)
• Thomsen, Maria; Guren, Marianne; Skovlund, Eva et al. (2017). Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. (ekstern lenke)
• Labori, Knut Jørgen; Lassen, Kristoffer; Hoem, Dag et al. (2017). Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. (ekstern lenke)
• Mezheyeuski, Artur; Strell, Carina; Hrynchyk, Ina et al. (2017). Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. (ekstern lenke)
• Ali, Abir Salwa; Grönberg, Malin; Federspiel, Birgitte et al. (2017). Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. (ekstern lenke)
• Angelsen, Jon-Helge; Horn, Arild; Sorbye, Halfdan et al. (2017). Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. (ekstern lenke)
• Perren, Aurel A.; Couvelard, Anne; Scoazec, Jean-Yves et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. (ekstern lenke)
• Pavel, Marianne; Valle, Juan W; Eriksson, Barbro et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. (ekstern lenke)
• Winther, Stine Brændegaard; Österlund, Pia; Berglund, Åke et al. (2017). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. (ekstern lenke)
• Garcia-Carbonero, Rocio; Rinke, Anja; Valle, Juan W et al. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. (ekstern lenke)
• Dumanski, Jan P.; Rasi, Chiara; Björklund, Peyman et al. (2017). A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. (ekstern lenke)
• Winther, S.B.; Østerlund, P.; Berglund, Å et al. (2016). NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan). (ekstern lenke)
• Thomsen, Maria; Kersten, Christian; Sorbye, Halfdan et al. (2016). Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. (ekstern lenke)
• Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen et al. (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. (ekstern lenke)
• Mezheyeuski, Artur; Lindh, Maja Bradic; Guren, Tormod Kyrre et al. (2016). Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. (ekstern lenke)
• Österlund, Pia; Sorbye, Halfdan; Pfeiffer, Per et al. (2016). Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. (ekstern lenke)
• Sveen, Anita; Løes, Inger Marie; Alagaratnam, Sharmini et al. (2016). Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. (ekstern lenke)
• Garcia-Carbonero, Rocio; Sorbye, Halfdan; Baudin, Eric et al. (2016). ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. (ekstern lenke)
• Tarpgaard, Line Schmidt; Ørum-Madsen, Maj Sofie; Christensen, Ib Jarle et al. (2016). TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. (ekstern lenke)
• Winther, Stine Brændegaard; Zubcevic, Kanita; Qvortrup, Camilla et al. (2016). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. (ekstern lenke)
• Haugvik, Sven-Petter; Janson, Eva Tiensuu; Osterlund, Pia et al. (2016). Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. (ekstern lenke)
• Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan et al. (2016). Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. (ekstern lenke)
• Tanis, Erik; Julié, Catherine; Emile, Jean-Francois et al. (2015). Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. (ekstern lenke)
• Pfeiffer, Per; Sorbye, Halfdan; Qvortrup, Camilla et al. (2015). Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. (ekstern lenke)
• Sorbye, Halfdan; Dragomir, Anca; Sundström, Magnus et al. (2015). High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. (ekstern lenke)
• Tarpgaard, Line Schmidt; Christensen, Ib J.; Høyer-Hansen, Gunilla et al. (2015). Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. (ekstern lenke)
• Joranger, Pål; Nesbakken, Arild; Hoff, Geir et al. (2015). Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. (ekstern lenke)
• Angelsen, Jon-Helge; Viste, Asgaut; Løes, Inger Marie et al. (2015). Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. (ekstern lenke)
• Poulsen, Laurids Ø.; Qvortrup, Camilla; Pfeiffer, Per et al. (2015). Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much?. (ekstern lenke)
• Tarpgaard, Line Schmidt; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2014). Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. (ekstern lenke)
• Tanis, Erik; Nordlinger, Bernard; Mauer, Murielle et al. (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. (ekstern lenke)
• Janson, Eva Tiensuu; Sorbye, Halfdan; Welin, Staffan et al. (2014). Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt et al. (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (ekstern lenke)
• Sorbye, Halfdan; Småstuen, Milada Cvancarova; Qvortrup, Camilla et al. (2013). Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. (ekstern lenke)
• Sorbye, Halfdan; Welin, Staffan; Langer, Seppo W. et al. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. (ekstern lenke)
• Trønnes, Håvard; Haugland, Hans Kristian; Bekassy, Albert N. et al. (2012). Small Cell Lung Cancer in a 14-Year-Old Girl. (ekstern lenke)
• Sorbye, Halfdan; Mauer, Murielle; Gruenberger, Thomas et al. (2012). Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). (ekstern lenke)
• Kjersem, Janne Beathe; Andersen, Tone Ikdahl; Guren, Tormod Kyrre et al. (2012). Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. (ekstern lenke)
• Tveit, Magne Kjell; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2012). Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. (ekstern lenke)
• Fassnacht, Martin; Terzolo, Massimo; Allolio, Bruno et al. (2012). Combination Chemotherapy in Advanced Adrenocortical Carcinoma. (ekstern lenke)
• Roy, Arunabha; Cunningham, David; Hawkins, Robert et al. (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. (ekstern lenke)
• Cavalli-Björkman, Nina; Qvortrup, Camilla; Sebjørnsen, Sigrunn et al. (2012). Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. (ekstern lenke)
• Glimelius, Bengt; Garmo, Hans; Berglund, Åke et al. (2011). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. (ekstern lenke)
• Welin, Staffan; Sørbye, Halfdan; Sebjørnsen, Sigrunn et al. (2011). Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. (ekstern lenke)
• Janson, ET; Sørbye, Halfdan; Welin, S et al. (2010). Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. (ekstern lenke)
• Sørbye, Halfdan; Pfeiffer, P; Cavalli-Bjorkman, N et al. (2009). Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. (ekstern lenke)
• Glimelius, Bengt; Sørbye, Halfdan; Balteskard, L et al. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. (ekstern lenke)
• Qvortrup, C; Yilmaz, M; Øgreid, Dagfinn et al. (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. (ekstern lenke)
• Sørbye, Halfdan (2008). Prognostic clinical factors in metastatic colorectal cancer. (ekstern lenke)
• Nordlinger, Bernard; Sørbye, Halfdan; Glimelius, Bengt et al. (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. (ekstern lenke)
• Hovdenak, Nils; Sørbye, Halfdan; Dahl, Olav (2005). SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. (ekstern lenke)
• Sørbye, Halfdan; Dahl, Olav (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. (ekstern lenke)
• Sørbye, Halfdan; Glimelius, Bengt; Berglund, Å et al. (2004). Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. (ekstern lenke)
• Hovdenak, Nils; Karlsdottir, Åsa; Sørbye, Halfdan et al. (2003). Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. (ekstern lenke)
• Sørbye, Halfdan; Dahl, Olav (2003). Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. (ekstern lenke)
• Sørbye, Halfdan; Dahl, Olav (2003). Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. (ekstern lenke)
• Øvrebø, Kjell Kåre; Svanes, Knut; Aase, Steinar Torbjørn et al. (2002). Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. (ekstern lenke)
• Øvrebø, Kjell Kåre; Aase, Steinar; Grong, Ketil et al. (2002). Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. (ekstern lenke)
• Øvrebø, Kjell Kåre; Svanes, Knut; Aase, Steinar et al. (2002). Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. (ekstern lenke)
• Sørbye, Halfdan; Bruserud, Øystein; Dahl, Olav (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. (ekstern lenke)
• Øvrebø, Kjell Kåre; Svardal, Asbjørn; Kvinnsland, Stener et al. (1999). Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. (ekstern lenke)
• Sørbye, Halfdan; Jensen, Dag; Dahl, Olav (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. (ekstern lenke)
• Sørbye, Halfdan; Jensen, Dag; Dahl, Olav (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. (ekstern lenke)
• Øvrebø, Kjell Kåre; Sørbye, Halfdan; Kvinnsland, Stener et al. (1998). Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. (ekstern lenke)
• Øvrebø, Kjell Kåre; Sørbye, Halfdan; Svardal, Asbjørn et al. (1997). Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. (ekstern lenke)
• Sørbye, Halfdan; Guttu, Kristian; Gislason, Hjørtur et al. (1993). Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. (ekstern lenke)

Vitenskapelig oversiktsartikkel/review

• Sorbye, Halfdan; Kong, Grace; Grozinsky-Glasberg, Simona et al. (2024). PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). (ekstern lenke)
• Dam, Gitte; Grønbæk, Henning; Sundlöv, Anna et al. (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. (ekstern lenke)
• Andreatos, Nikolaos; McGarrah, Patrick W.; Sonbol, Mohamad Bassam et al. (2023). Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. (ekstern lenke)
• Sorbye, Halfdan; Kong, Grace; Grozinsky-Glasberg, Simona (2020). PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). (ekstern lenke)
• Goey, Kaitlyn K.H.; Mahmoud, Remi; Sorbye, Halfdan et al. (2018). Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. (ekstern lenke)
• Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob et al. (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. (ekstern lenke)
• Sorbye, Halfdan; Strosberg, Jonathan; Baudin, Eric et al. (2014). Gastroenteropancreatic high-grade neuroendocrine carcinoma. (ekstern lenke)
• Biermann, Martin; Johnsen, Boel; Sørbye, Halfdan et al. (2009). Positronemisjonstomografi ved nevroendokrine svulster. (ekstern lenke)
• Sørbye, Halfdan; Brændengen, M; Balteskard, L (2008). Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. (ekstern lenke)

Doktorgradsavhandling

• Elvebakken, Hege; Sørbye, Halfdan; Hofsli, Eva et al. (2023). High-grade digestive neuroendocrine neoplasms. Impact of genetic alterations and morphologicalcharacteristics on outcome of first-line palliative chemotherapy. (ekstern lenke)
• Sørbye, Halfdan (1994). Penetration of carcinogens into normal and damaged gastric mucosa. (ekstern lenke)

Poster

• Meltzer, Sebastian; Negård, Anne; Hamre, Hanne Mari et al. (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).. (ekstern lenke)
• Ree, Anne Hansen; Hamre, Hanne Mari; Kersten, Christian et al. (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study. (ekstern lenke)
• Joranger, Pål; Nesbakken, Arild; Hoff, Geir et al. (2014). Development and validation of a Norwegian model for colorectal cancer. (ekstern lenke)
• Sørbye, Halfdan; Glimelius, Bengt; Berglund, Åke et al. (2003). Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer. (ekstern lenke)
• Guttu, K; Sorbye, Halfdan; Svanes, K. et al. (1993). Effect of restricted hyperaemic response and systemic alkalinization on gastric luminal bicarbonate release and mucosal restitution after hyperomolar damage in the cat.. (ekstern lenke)

Sammendrag/abstract

• Knappskog, Stian; Sorbye, Halfdan; Grob, Tim et al. (2022). Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients. (ekstern lenke)
• Butt, Baddar Pervaiz; Stokmo, Henning Langen; Rootwelt-Revheim, Mona Elisabeth et al. (2021). Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas. (ekstern lenke)
• Sorbye, Halfdan; Venizelos, Andreas; Elvebakken, Hege et al. (2021). Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. (ekstern lenke)
• Pfeiffer, Per; Glimelius, Bengt; Winther, Stine Brændegaard et al. (2019). Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. (ekstern lenke)
• Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav et al. (2018). Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. (ekstern lenke)
• Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen et al. (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. (ekstern lenke)
• Sorbye, Halfdan; Welin, Staffan; Langer, Seppo et al. (2013). Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). (ekstern lenke)
• Qvortrup, C; Cvancarova, M; Glimelius, B. et al. (2012). AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. (ekstern lenke)
• Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt et al. (2012). Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. (ekstern lenke)
• Sorbye, Halfdan; Welin, Staffan; Langer, Seppo W. et al. (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. (ekstern lenke)
• Pfeiffer, Per; Sorbye, Halfdan; Qvortrup, Camilla et al. (2012). Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. (ekstern lenke)
• Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt et al. (2012). EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. (ekstern lenke)
• Tarpgaard, Line Schmidt; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2012). Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. (ekstern lenke)
• Tveit, Magne Kjell; Guren, Tormod Kyrre; Glimelius, Bengt et al. (2010). Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. (ekstern lenke)
• Gruenberger, T; Sørbye, Halfdan; Debois, M et al. (2006). Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. (ekstern lenke)
• Nordlinger, B; Sørbye, Halfdan; Debois, M et al. (2005). Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. (ekstern lenke)
• Svanes, K; Gislason, Hjørtur; Grønbech, Jon Erik et al. (1993). Role of blood flow in the healing of gastric mucosal lesions. . (ekstern lenke)

Leserinnlegg

• Sorbye, Halfdan (2019). Ekspertpanel for ny vurdering ved alvorlig sykdom. (ekstern lenke)

Errata

• Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob et al. (2016). Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). (ekstern lenke)

Brev til redaktøren

• Sorbye, Halfdan; Mauer, Murielle; Nordlinger, Bernard (2015). Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)". (ekstern lenke)

Vitenskapelig foredrag

• Joranger, Pål; Nesbakken, Arild; Hoff, Geir et al. (2015). Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer. (ekstern lenke)
• Glimelius, Bengt; Sørbye, Halfdan; Balteskard, L et al. (2005). A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer. (ekstern lenke)

Vitenskapelig Kapittel/Artikkel/Konferanseartikkel

• Sorbye, Halfdan (2014). Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. (ekstern lenke)
• Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Hoem, Dag et al. (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. (ekstern lenke)
• Telhaug, Ragnar; Varhaug, Jan Erik; Sørbye, Halfdan et al. (2009). Endokrine svulster. (ekstern lenke)
• Sørbye, Halfdan (2008). The use of Chemotherapy for Neuroendocrine Tumors. (ekstern lenke)
• Bremnes, RM; Endresen, P; Sørbye, Halfdan (1999). Antimetabolitter. (ekstern lenke)

Leder

• Sorbye, Halfdan (2012). Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?. (ekstern lenke)

Short communication

• Nordlinger, B; Gruenberger, T; Sørbye, Halfdan et al. (2008). Surgery vs surgery and chemotherapy for colorectal liver metastases. (ekstern lenke)

Rapport

• Aaserud, Morten; Kristiansen, Ivar Sønbø; Neilson, Aileen Rae et al. (2007). Health economic evaluation of bevacizumab for metastatic colorectal cancer. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin